Boston Scientific Corporation (NYSE:BSX) Q4 2025 Earnings Call Transcript February 4, 2026 Boston Scientific Corporation ...
January 22, 2026—Boston Scientific announced it has received CE Mark approval for the company’s Embold detachable coil system, which is a new generation of fully retractable embolization coils ...
Boston Scientific has agreed to acquire Penumbra in a cash-and-stock deal worth $14.5 billion.
Good morning, and welcome to the Boston Scientific Investor Update. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, ...
Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio. Boston Scientific on Thursday said the ...
Boston Scientific inks $14.5B deal, boosting its Minnesota-dominated heart device portfolio Boston Scientific has long used mergers and acquisitions to fuel growth. This deal appears to be its largest ...
Boston Scientific Corp. agreed to buy medical device maker Penumbra Inc. in a deal valued at more than $14 billion to expand in the treatment of blood clots and stroke. Boston Scientific said it will ...
[Image from Boston Scientific President, Peripheral Vascular, Catherine Jennings on LinkedIn] A Boston Scientific (NYSE: BSX) + today took to social media to share news of the first peripheral cases ...
Hosted on MSN
Boston Scientific earnings preview: What to expect
Boston Scientific Corporation (BSX), headquartered in Marlborough, Massachusetts, develops, manufactures, and markets medical devices for use in various interventional medical specialties globally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results